Clinical Trials Sponsored by Optomed

Total 66 results

Sublimed
Eurofins Optimed

Unknown

Comparison of the Efficacy, Tolerability and Safety of actiTENS to Those of Level 2 Analgesic Treatments. (ArthroTENS)

Knee Osteoarthritis

France
Enterome
Eurofins Optimed

Terminated

MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients (MOBIDIC)

Crohn's Disease

United States, France, United Kingdom
OptMed, Inc.

Completed

Safety and Efficacy Study of BondEase to Treat Traumatic Lacerations and Surgical Incisions

Traumatic Lacerations or Surgical Incisions

United States
Mapreg
Eurofins Optimed

Recruiting

RESIST : Administration of MAP4343 in Antidepressant Non-Responders Patients Experiencing a Major Depressive Episode

Depression

France
Optimed Medizinische Instrumente GmbH

Completed

Treatment of the Postthrombotic Syndrome With the Oblique Stent - TOPOS Study

Post-thrombotic Syndrome | Iliac Vein Compression Syndrome

Switzerland, Austria, Germany, Netherlands
CytoMed & Beike

Unknown

Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis (hUC-MSC-SLE)

Lupus Nephritis

China
Amazentis SA
Eurofins Optimed

Completed

A Single and Multiple Dose Study of AMAZ-02 to Evaluate Safety and Pharmacokinetics in Elderly Subjects

Aging | Muscle Function | Mitochondrial Dysfunction

France
Lesaffre International
Eurofins Optimed

Terminated

Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis

Vulvo-vaginal Candidiasis

France
Ypsomed AG

Completed

Extended Wear of a Steel and a Teflon Insulin Infusion Set

Diabetes Mellitus, Type 1

Germany
Quantum Genomics SA
Eurofins Optimed

Completed

Pharmacokinetics in End Stage Renal Disease Patients

Renal Failure | Healthy Volunteers

France
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

RI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Renal Impaired Patients and Healthy Subjects

Healthy Volunteers | Impaired Renal Function

France, Hungary
Danisco Sweeteners Oy
Eurofins Optimed

Completed

Effects of Probiotic Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Constipation.

Constipation | Gastrointestinal Disorder

France
Dr. Martin Leitritz
Optomed

Completed

Comparison of Non-mydriatic Camera Systems in a Female Health Hospital

Eye Diseases | Retina; Lesion | Optic Disc Structural Anomaly

Germany
Optimer Pharmaceuticals LLC

Completed

Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001) (DEFLECT-1)

Clostridium Difficile-Associated Diarrhea (CDAD)
Optimer Pharmaceuticals LLC

Completed

Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers

Acute Bacterial Gastroenteritis

India
MedDay Pharmaceuticals SA
Eurofins Optimed

Terminated

HI Study to Assess and Compare the Pharmacokinetic Parameters of MD1003 in Hepatic Impaired Patients and Healthy Subjects

Healthy Volunteers | Hepatic Impairment of Moderate Child Pugh Category

France, Hungary
Yoplait France SAS
Eurofins Optimed

Completed

Effect of Consumption of Yogurt Fortified in Calcium and Vit. D on Circulating Levels of 25OHD in Postmenopausal Women

Vitamin D Deficiency | Menopause

France
Danisco France SAS
Eurofins Optimed

Completed

Effect of Study Probiotics on Body Fat Mass in Overweight and Obese Individuals Following Healthy Lifestyle Intervention (QLSlimCapHL)

Obesity | Overweight

France, Spain
Unilever R&D
Eurofins Optimed

Completed

Comparison of the Satiety Effect of a Very Low Energy Foam With Normal Energy Foams

Satiety | Appetite
Bledina
Optimed Medizinische Instrumente GmbH

Completed

Prevention of Cow's Milk Allergy in Children

Milk Hypersensitivity

France
OrphoMed, Inc.
PPD

Completed

A Comparison of the Effects of ORP-101 Versus Placebo in Adult Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D)

Irritable Bowel Syndrome With Diarrhea

United States
Optimer Pharmaceuticals LLC

Completed

PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)

Diarrhea | Clostridium Infections

United States, France, United Kingdom, Belgium, Spain, Canada, Germany, Italy, Sweden
Optimer Pharmaceuticals LLC

Completed

OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)

Diarrhea

United States
Optimer Pharmaceuticals LLC

Completed

Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

Clostridium Difficile-associated Diarrhea
Optimer Pharmaceuticals LLC

Completed

Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)

Diarrhea | Clostridium Infections
Genfit
Eurofins Optimed; PhinC Development; CardiaBase

Completed

Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers

Healthy Volunteers

France
CytoMed Therapeutics Pte Ltd

Unknown

Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour

Sarcoma | Nasopharyngeal Carcinoma | Gastric Cancer | Colorectal Cancer | Prostate Cancer | Triple Negative Breast Cancer

Malaysia
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian (SIERRA)

Primary Peritoneal Carcinoma

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors

Relapsed or Refractory Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors

Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer

Metastatic Breast Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Completed

Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

Ovarian Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors

Advanced Solid Tumor Malignancies

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

United States
Hartford Hospital
Optimer Pharmaceuticals LLC

Completed

Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin

Clostridium Difficile Infection

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer (ALPINE)

Stage IV Pancreatic Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1 Dose Escalation Study of OMP-21M18 in Subjects With Solid Tumors

Solid Tumors

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy (PINNACLE)

Stage IV Small Cell Lung Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Relapsed or Refractory Lymphoid Malignancies

United States
OncoMed Pharmaceuticals, Inc.

Completed

Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer

Pancreatic Cancer | Stage IV Pancreatic Cancer

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer

Cancer Ovaries | Cancer Peritoneal | Cancer, Fallopian Tube

United States
OncoMed Pharmaceuticals, Inc.

Completed

A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10

Refractory Solid Tumors | Advanced Relapsed Tumors

United States
OncoMed Pharmaceuticals, Inc.

Completed

Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

Liver Cancer | Hepatocellular Cancer

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors

Metastatic Cancer | Locally Advanced Malignant Neoplasm

United States
OncoMed Pharmaceuticals, Inc.

Terminated

A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

Metastatic Cancer | Locally Advanced Cancer

United States
Calliditas Therapeutics AB
Eurofins Optimed; York Bioanalytical Solution

Completed

Comparison of the Relative Oral Bioavailability of GKT137831 Formulated in Capsules or in Tablets

Phase 1

France

3

Subscribe